64th ASH Annual Meeting and Exposition: 905. Outcomes Research—Lymphoid Malignancies: Outcomes in Lymphoma

Symposia: Outcomes Research—Lymphoid Malignancies Oral and Poster Abstracts
Oral

Research, adult, Lymphoid Leukemias, Lymphomas, Clinical Practice (Health Services and Quality), epidemiology, CLL, Non-Biological therapies, non-Hodgkin lymphoma, elderly, Clinical Research, health outcomes research, B Cell lymphoma, Combination therapy, T Cell lymphoma, Diseases, indolent lymphoma, patient-reported outcomes, real-world evidence, Therapies, aggressive lymphoma, Lymphoid Malignancies, Adverse Events, survivorship, Study Population, Human

388-390 (Ernest N. Morial Convention Center)

Moderators:

Jean L. Koff, MD, MSc, Emory University and Ning Dong, H. Lee Moffitt Cancer Center and Research Institute

Disclosures:

No relevant conflicts of interest to declare.

This session gives the updates and outcomes in conditions related to lymphoma

10:30 AM

793

Development of a Conditional Event-Free Survival Tool in Diffuse Large B-Cell Lymphoma

Danny Luan, MD, MPH¹, Chen Zhengming, PhD, MPH, MS¹^*, Lasse Hjort Jakobsen, MSc, PhD²^*, Matthew J. Maurer, DSc³, Tarec Christoffer Christoffer El-Galaly, MD, DSc⁴, Loretta J. Nastoupil, MD⁵, James R. Cerhan, MD, PhD⁶, Christopher R. Flowers, MD⁵, Brian K. Link, MD⁷, Izidore S. Lossos, MD⁸, Deborah M. Stephens, DO⁹, Thomas M. Habermann, MD¹⁰, Grzegorz S. Nowakowski, MD¹¹, Nancy L. Bartlett, MD¹², Jonathan W. Friedberg, MD, MMSc¹³, Brad S. Kahl, MD¹⁴, John P. Leonard, MD¹⁵, Peter De Nully Brown, MD¹⁶, Karin E. Smedby, MD, PhD¹⁷^*, Mats Jerkeman, MD, PhD¹⁸ and Peter Martin, FRCPC, MD, MS¹⁹

¹Weill Cornell Medicine, New York, NY
²Department of Clinical Medicine, Aalborg University, Aalborg, Denmark
³Department of Quantitative Health Sciences Research, Mayo Clinic, Rochester, MN
⁴Department of Hematology, Clinical Cancer Research Center, Aalborg University Hospital, Aalborg, Denmark
⁵Department of Lymphoma and Myeloma, MD Anderson Cancer Center, Houston, TX
⁶Department of Quantitative Health Sciences, Mayo Clinic, Rochester, MN
⁷Division of Hematology, Oncology, and Blood & Marrow Transplantation, University of Iowa, Iowa City, IA
⁸Sylvester Comprehensive Cancer Center, University of Miami School of Medicine, Miami, FL
⁹Huntsman Cancer Institute, Salt Lake City, UT
¹⁰Division of Hematology, Department of Medicine, Mayo Clinic, Rochester, MN
¹¹Division of Hematology, Mayo Clinic, Rochester, MN
¹²Siteman Cancer Center, Washington University School of Medicine, St. Louis, MO
¹³James P. Wilmot Cancer Center, University of Rochester Medical Center, Rochester, NY
¹⁴Division of Oncology, Washington University School of Medicine in St. Louis, Saint Louis, MO
¹⁵Weill Cornell Medicine and New York Presbyterian Hospital, New York, NY
¹⁶Department of Hematology, Copenhagen University Hospital Rigshospitalet, Copenhagen, Denmark
¹⁷Karolinska University Hospital, Stockholm, Sweden
¹⁸Skane University Hospital and Lund University, Lund, Skaane Laen, Sweden
¹⁹Meyer Cancer Center, Weill Cornell Medical College-New York Presbyterian Hospital, New York, NY

10:45 AM

794

A Novel, Clinically Adaptable Comorbidity Assessment Tool for Non-Hodgkin Lymphoma (NHL), the Three-Factor Risk Estimate Scale (TRES): Analysis of 40,000 Older Adults Enrolled in SEER-Medicare

Max J. Gordon, MD¹, Zhigang Duan, MS²^*, Hui Zhao³^*, Loretta J. Nastoupil, MD⁴, Alessandra Ferrajoli⁵, Alexey Danilov, MD, PhD⁶^* and Sharon Giordano, MD⁷^*

¹University of Texas MD Anderson, Houston
²University of Texas MD Anderson, Texas, TX
³University of Texas MD Anderson Cancer Center, Houston, TX
⁴Department of Lymphoma and Myeloma, MD Anderson Cancer Center, Houston, TX
⁵Department of Leukemia, The University of Texas M.D. Anderson Cancer Center, Houston, TX
⁶City of Hope National Medical Center, Duarte, CA
⁷University of Texas MD Anderson, Houston, TX

11:00 AM

795

Early Relapse within 24 Months after Frontline Systemic Therapy (POD24) Is Associated with Worse Survival in Patients with Marginal Zone Lymphoma: A US Multisite Study

Narendranath Epperla, MD, MS¹, Rui Li, MPH²^*, Pallawi Torka, MD³, Lauren Shea⁴^*, Reem Karmali, MD, MSc⁵, Andrea Anampa-Guzman, MD³^*, Timothy Seijung Oh, MD⁶^*, Kathryn Lindsey, MD⁷^*, Irl Brian Greenwell, MD⁷, Sayan Mullick Chowdhury, DO, PhD⁸^*, Kaitlin Annunzio, DO⁹, Beth Christian¹⁰, Geoffrey Shouse, PhD, DO¹¹, Alex F. Herrera, MD¹², Nancy L. Bartlett, MD¹³, Natalie S. Grover, MD¹⁴ and Adam J. Olszewski, MD¹⁵

¹The Ohio State University Comprehensive Cancer Center - Arthur G. James Cancer Hospital and Richard J. Solove Research Institute, Columbus, OH
²Division of Hematology, The Ohio State University, Columbus, OH
³Roswell Park Comprehensive Cancer Center, Buffalo, NY
⁴University of Alabama At Birmingham, Birmingham, AL
⁵Robert H. Lurie Comprehensive Cancer Center, Division of Hematology/Oncology, Feinberg School of Medicine, Northwestern University, Chicago, IL
⁶Robert H. Lurie Comprehensive Cancer Center of Northwestern University, Chicago, IL
⁷Hollings Cancer Center, Medical University of South Carolina, Charleston, SC
⁸Ohio State University Medical Center, Columbus, OH
⁹The Ohio State University, Columbus, OH
¹⁰The Ohio State University Comprehensive Cancer Center, Columbus, OH
¹¹Department of Hematology and Hematopoietic Cell Transplantation, City of Hope, Duarte, CA
¹²City of Hope, Duarte, CA
¹³Siteman Cancer Center, Washington University School of Medicine, St. Louis, MO
¹⁴Lineberger Comprehensive Cancer Center, University of North Carolina, Chapel Hill, NC
¹⁵Division of Hematology/Oncology, Brown University, Providence, RI

11:15 AM

796

Fatigue, Neuropathy, Psychological Distress and Their Association with Health-Related Quality of Life in Survivors of Diffuse Large B-Cell Lymphoma: A Prospective Cohort Study and Comparison with a Normative Population

Suzanne Neppelenbroek¹^*, Afke Ekels, MSc^2,3^*, Marie Jose Kersten, MD, PhD⁴, Flora Van Leeuwen, Dr. Ir.⁵^*, Djamila E. Issa, MD, PhD⁶^*, Noortje Thielen, MD, PhD⁷^*, Lonneke van de Poll-Franse, PhD^8,9,10^* and Simone Oerlemans, PhD⁹^*

¹Department of Psychosocial Research and Epidemiology, The Netherlands Cancer Institute, Amsterdam, Netherlands
²Research and Development, Netherlands Comprehensive Cancer Organisation (IKNL), Utrecht, AL, Netherlands
³Department of Psychosocial Research and Epidemiology, The Netherlands Cancer Institute, Amsterdam, Amsterdam, Netherlands
⁴Department of Hematology, Academic Medical Center, Amsterdam, Noord Holland, Netherlands
⁵Department of Psychosocial Research and Epidemiology, Netherlands Cancer Institute, Amsterdam, Netherlands
⁶Department of Hematology, Jeroen Bosch Hospital, Den Bosch, Netherlands
⁷Department of Internal Medicine, Diakonessenziekenhuis, Utrecht, Netherlands
⁸Department of Psychosocial Research, Division of Psychosocial Research & Epidemiology, The Netherlands Cancer Institute, Amsterdam, Amsterdam, Netherlands
⁹Research and Development, Netherlands Comprehensive Cancer Organisation (IKNL), Utrecht, Netherlands
¹⁰Department of Medical and Clinical Psychology, Tilburg University, Tilburg, Netherlands

11:30 AM

797

Real-World Comparison of Time to Next Treatment for Patients with CLL Initiated on First-Line Treatment with Ibrutinib Versus Acalabrutinib

Ryan Jacobs, MD¹^*, Xiaoxiao Lu, PhD, MD, MPH²^*, Bruno Emond, MSc³^*, Laura Morrison, MPH³^*, Frédéric Kinkead, MA³^*, Patrick Lefebvre, MA³^*, Marie-Hélène Lafeuille, MA³^*, Wasiulla Khan, PhD²^*, Linda Wu, PhD²^*, Zaina P. Qureshi, PhD, MS, MPH²^* and Moshe Yair Levy, MD⁴

¹Hematology, Atrium Health Levine Cancer Institute, Charlotte, NC
²Janssen Scientific Affairs, LLC, Horsham, PA
³Analysis Group, Inc., Montreal, QC, Canada
⁴Baylor Scott & White Research Institute, Dallas, TX

11:45 AM

798

Incidence of Second Primary Malignancies in Lymphoma Survivors: A Prospective Cohort Study in the Modern Treatment Era

Sanjal H Desai, MBBS^1,2, Raphael Mwangi, MS³^*, Yucai Wang, MD, PhD⁴, Umar Farooq, MD⁵, Eric Mou, MD⁶^*, Andrew L. Feldman, MD⁷, Sergei Syrbu, MD, PhD⁸^*, Susan L. Slager, PhD⁹, Grzegorz S. Nowakowski, MD², Matthew J. Maurer, DSc⁹, Neil E. Kay, MD⁴, Thomas M. Habermann, MD⁴, Brian K. Link, MD⁵, Carrie A. Thompson, MD² and James R. Cerhan, MD, PhD⁹

¹University of Minnesota, Division of Hematology Oncology Transplantation, Minneapolis, MN
²Division of Hematology, Mayo Clinic, Rochester, MN
³Department of Quantitative Health Sciences Research, Mayo Clinic, Rochester, MN
⁴Division of Hematology, Department of Medicine, Mayo Clinic, Rochester, MN
⁵Division of Hematology, Oncology, and Blood & Marrow Transplantation, University of Iowa, Iowa City, IA
⁶University of Iowa, Iowa City, IA
⁷Department of Laboratory Medicine and Pathology, Mayo Clinic, Rochester, MN
⁸Department of Pathology, University of Iowa, Iowa City, IA
⁹Department of Quantitative Health Sciences, Mayo Clinic, Rochester, MN

See more of: Oral and Poster Abstracts

<< Previous Session | Next Session >>

^*signifies non-member of ASH

905.O3.6 905. Outcomes Research—Lymphoid Malignancies: Outcomes in Lymphoma